

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6606)**

**VOLUNTARY ANNOUNCEMENT**

**NMPA Approval for Registration Application of UU Tube®**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**” or “**We**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development progress of the Group.

The Company is pleased to announce that on January 6, 2022, the Company received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局) (“**NMPA**”) of the registration application for UU Tube® as Class III medical device, the Company’s stool-based self-conducted screening product for gastric cancer by detecting H. pylori, the pathogenic bacteria which is the major causative agent for gastric cancer.

Our self-developed UU Tube® is the first self-conducted screening product for H. pylori approved by NMPA and integrates the design of sampling and testing into one device. It is easy for consumers to use without the need of taking medication before testing or fasting and there are no special requirements in its sample collection.

**Cautionary statement under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that UU Tube® will ultimately be successfully commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**New Horizon Health Limited**  
**Dr. Yiyou CHEN**  
*Chairman*

Hong Kong, January 6, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiyou CHEN as Chairman and executive Director, Mr. Yeqing ZHU as executive Director, Mr. Naxin YAO and Ms. Nisa Bernice Wing-Yu LEUNG as non-executive Directors, and Mr. Danke YU, Prof. Hong WU and Dr. Kwok Tung LI, Donald as independent non-executive Directors.*